Tags

Type your tag names separated by a space and hit enter

Preliminary experience on treatment of insulin-dependent diabetes mellitus with a long-acting somatostatin analogue (L363,586).
Horm Res. 1988; 29(2-3):95-8.HR

Abstract

L363,586 is a potent, long-acting, somatostatin derivative. Intravenous and intranasal administration to diabetic subjects was effective in reducing both fasting and postprandial hyperglycemia. Also in patients stabilized on a closed-loop insulin infusion device, the intranasal administration of L363,586 was able to improve the glucose imbalance known as dawn phenomenon. Therefore, this analogue associated to standard insulin replacement could be useful in the control of unstable diabetes.

Authors+Show Affiliations

Bolli GB
Istituto di Patologia Medica, Università di Perugia, Italia.
Gottesman IS
No affiliation info available
Gerich JE
No affiliation info available

MeSH

Blood GlucoseCircadian RhythmDiabetes Mellitus, Type 1Drug Administration ScheduleHumansPeptides, CyclicSomatostatin

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

2900206

Citation

Bolli, G B., et al. "Preliminary Experience On Treatment of Insulin-dependent Diabetes Mellitus With a Long-acting Somatostatin Analogue (L363,586)." Hormone Research, vol. 29, no. 2-3, 1988, pp. 95-8.
Bolli GB, Gottesman IS, Gerich JE. Preliminary experience on treatment of insulin-dependent diabetes mellitus with a long-acting somatostatin analogue (L363,586). Horm Res. 1988;29(2-3):95-8.
Bolli, G. B., Gottesman, I. S., & Gerich, J. E. (1988). Preliminary experience on treatment of insulin-dependent diabetes mellitus with a long-acting somatostatin analogue (L363,586). Hormone Research, 29(2-3), 95-8.
Bolli GB, Gottesman IS, Gerich JE. Preliminary Experience On Treatment of Insulin-dependent Diabetes Mellitus With a Long-acting Somatostatin Analogue (L363,586). Horm Res. 1988;29(2-3):95-8. PubMed PMID: 2900206.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Preliminary experience on treatment of insulin-dependent diabetes mellitus with a long-acting somatostatin analogue (L363,586). AU - Bolli,G B, AU - Gottesman,I S, AU - Gerich,J E, PY - 1988/1/1/pubmed PY - 1988/1/1/medline PY - 1988/1/1/entrez SP - 95 EP - 8 JF - Hormone research JO - Horm Res VL - 29 IS - 2-3 N2 - L363,586 is a potent, long-acting, somatostatin derivative. Intravenous and intranasal administration to diabetic subjects was effective in reducing both fasting and postprandial hyperglycemia. Also in patients stabilized on a closed-loop insulin infusion device, the intranasal administration of L363,586 was able to improve the glucose imbalance known as dawn phenomenon. Therefore, this analogue associated to standard insulin replacement could be useful in the control of unstable diabetes. SN - 0301-0163 UR - https://www.unboundmedicine.com/medline/citation/2900206/Preliminary_experience_on_treatment_of_insulin_dependent_diabetes_mellitus_with_a_long_acting_somatostatin_analogue__L363586__ DB - PRIME DP - Unbound Medicine ER -